Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk

References

• What is Atrial Fibrillation (AFib or AF)? American Heart Association. Updated 10 December 2014. Available at: http://www.heart.org/HEARTORG/Conditions/Arrhythmia/AboutArrhythmia/What-is-Atrial-Fibrillation-AFib-or-AF_UCM_423748_Article.jsp [Last accessed 31 July 2015]
   Google Scholar
• Anon. Cardiogenic brain embolism. Arch Neurol 1986;43:71-84
   PubMedGoogle Scholar
• Han SW, Nam HS, Kim SH, et al. Frequency and significance of cardiac sources of embolism in the TOAST classification. Cerebrovasc Dis (Basel, Switzerland) 2007;24:463-8
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67
   PubMed Web of Science ®Google Scholar
• Van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009;40:1410-16
   PubMed Web of Science ®Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72
   PubMed Web of Science ®Google Scholar
• Furie KL, Goldstein LB, Albers GW, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012;43:3442-53
   PubMed Web of Science ®Google Scholar
• Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:3754-832
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol 2014;64:2246-80
   Web of Science ®Google Scholar
• You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e531S-75S
   PubMed Web of Science ®Google Scholar
• Zimetbaum PJ, Thosani A, Yu H-T, et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med 2010;123:446-53
   PubMed Web of Science ®Google Scholar
• Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010;123:638-45.e4
   PubMed Web of Science ®Google Scholar
• Casciano JP, Dotiwala ZJ, Martin BC, Kwong WJ. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. J Manag Care Pharm 2013;19:302-16
   PubMed Web of Science ®Google Scholar
• Skeppholm M, Friberg L. Adherence to warfarin treatment among patients with atrial fibrillation. Clin Res Cardiol 2014;103:998-1005
   PubMed Web of Science ®Google Scholar
• Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013;6:567-74
   PubMed Web of Science ®Google Scholar
• Riva N, Smith DE, Lip GYH, Lane DA. Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation. Age Ageing 2011;40:653-5
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429
   PubMed Web of Science ®Google Scholar
• Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2006;48:854-906
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999;131:927-34
   PubMed Web of Science ®Google Scholar
• Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011;58:395-401
   PubMed Web of Science ®Google Scholar
• Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 2010;3:624-31
   PubMed Web of Science ®Google Scholar
• Deitelzweig SB, Buysman E, Pinsky B, et al. Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Therapeut 2013;35:1201-10
   PubMed Web of Science ®Google Scholar
• Go AS, Singer D, Cheetman C, et al. Mini-Sentinel Medical Product Assessment: A Protocol for Assessment of Dabigatran. Sentinel Initiative. 2013. Available at: http://www.mini-sentinel.org/work_products/Assessments/Mini-Sentinel_Protocol-for-Assessment-of-Dabigatran.pdf [Last accessed 31 July 2015]
   Google Scholar
• Cunningham A, Stein CM, Chung CP, et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf 2011;20:560-6
   PubMed Web of Science ®Google Scholar
• Azoulay L, Dell’aniello S, Simon TA, et al. Initiation of warfarin in patients with atrial fibrillation: Early effects on ischaemic strokes. Eur Heart J 2014;35:1881-7
   PubMed Web of Science ®Google Scholar
• Fosbol EL, Holmes DN, Piccini JP, et al. Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. J Am Heart Assoc 2013;2:e000110
   PubMed Web of Science ®Google Scholar
• O’Brien EC, Kim S, Thomas L, et al. Abstract 14: clinical characteristics and treatment patterns of medicaid patients with atrial fibrillation: insights from the ORBIT-AF I Registry. Circ Cardiovasc Qual Outcomes 2015;8:A14
   Google Scholar
• DiMarco JP, Flaker G, Waldo AL, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005;149:650-6
   PubMed Web of Science ®Google Scholar
• Gomes T, Mamdani MM, Holbrook AM, et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. Can Med Assoc J 2013;185:E121-7
   PubMed Web of Science ®Google Scholar
• Abdelhafiz AH, Wheeldon NM. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic. Clin Therapeut 2004;26:1470-8
   PubMed Web of Science ®Google Scholar
• Murphy JE. Clinical Pharmacokinetics (5th Edition). In: Murphy JE, ed. 5th ed. Wisconsin: American Society of Health-System Pharmacists, 2011:351-72
   Google Scholar
• Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2013;61:386-7
   PubMed Web of Science ®Google Scholar